收涨100%！这家0收入创新药企要火？

Group 1 - The core viewpoint of the article highlights the significant market interest in Weili Zhizhi Bo, an unprofitable innovative drug company, which is set to list on the Hong Kong Stock Exchange, with its shares surging 100.14% in dark pool trading before the official listing [2][3]. - Weili Zhizhi Bo plans to issue 32.0544 million shares at an IPO price range of HKD 31.60 to HKD 35.00, with a total fundraising amount of approximately HKD 1.067 billion based on the midpoint of the offering price [2][3]. - The company has attracted a substantial subscription interest, with a financing subscription multiple exceeding 3000 times and total subscription amount reaching HKD 330 billion [2]. Group 2 - Weili Zhizhi Bo's cornerstone investors include prominent firms such as Tencent, E Fund, Zhengxin Valley Capital, and Gao Yi, indicating strong backing from established players in the industry [3]. - The company's core business model focuses on the discovery, development, and commercialization of tumor immunotherapy, with one core product (LBL-024) and 13 other candidate drugs, of which 6 have entered clinical stages [3]. - The company reported a revenue of HKD 8.865 million in 2023, but projected no revenue for 2024 and the first quarter of 2025, with net losses of HKD 362 million, HKD 301 million, and HKD 75.367 million respectively [4].